Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Uromedica · NCT04248283
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 22+ · Women only
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 167
- US sites recruiting
- 4
- Study start
- January 26, 2021
- Record last updated
- October 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Being studied: Adjustable Continence Therapy for Women (ACT)
Conditions: Urinary Incontinence; Urinary Incontinence,Stress
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Female at least 22 years old
- Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
- Provocative pad weight of greater than 11.0 grams
- Candidate for surgical intervention
- Negative urinalysis
- Normal cystourethroscopy
- Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
- Willing and able to sign informed consent and comply with trial follow-up requirements
Exclusion Criteria
- Pregnant or lactating
- Life expectancy of less than 5 years
- Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
- Has auto-immune disease
- Undergoing radiation therapy
- Active urinary tract infection
- Detrusor instability refractory to medication
- Reduced bladder compliance as defined by a cystometrogram
- Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
- Has, had, or is suspected of having bladder cancer
- History of bladder stones
- Urethral stricture evidenced during cystourethroscopy
- Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
- Has a diathesis, hemophilia, or a bleeding disorder
- Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
- Had prior pelvic radiotherapy
- Had a prior artificial urinary sphincter implanted
- Has a neurogenic condition known to affect bladder/sphincter function
Recruiting US locations
University of Colorado
Denver, CO 80045
Site contact: Andrea Pina · andrea.pinalimones@cuanschutz.edu
Idaho Urologic Institute, PA
Meridian, ID 83642
Site contact: Karrie Fox · karried@idurolog.com
CHI Health Research Center
Omaha, NE 68124
Site contact: Jodi Salvatori, RN, BSN · 402-343-8511 · jodi.salvatori@commonspirit.org
Penn State University
Hershey, PA 17033
Site contact: Jocelyn Chavla · jchavla@pennstatehealth.psu.edu
Study contacts (from the official record)
- Lisa Draper · 612-834-7494 · USLDR@COLOPLAST.COM
- Matt Kelly, PhD · 612-469-8882 · usmtk@coloplast.com